In March 2025, the Advisory Committee on Dangerous Pathogens (ACDP) advised that clade I mpox no longer meets the criteria for a high consequence infectious disease (HCID) and recommended derogation.

The open-label extension study in chronic urticarias is enrolling participants from the BEACON study as well as the SPOTLIGHT study in CIndU upon completion of their initial follow up period.